How much profit has 3SBio made this year?
3SBio has made 1.94 B CNY this year.
3SBio Net Income 2024
3SBio Net Income
1.94 B CNY
Ticker
1530.HK
ISIN
KYG8875G1029
WKN
A14T7Q
In 2024, 3SBio's profit amounted to 1.94 B CNY, a 25.41% increase from the 1.55 B CNY profit recorded in the previous year.
The 3SBio Net Income history
| YEAR | NET INCOME (undefined CNY) |
|---|---|
| 2029e | - |
| 2028e | - |
| 2027e | 1.38 |
| 2026e | 2.24 |
| 2025e | 2.12 |
| 2024e | 1.94 |
| 2023 | 1.55 |
| 2022 | 1.92 |
| 2021 | 1.65 |
| 2020 | 0.84 |
| 2019 | 0.97 |
| 2018 | 1.28 |
| 2017 | 0.94 |
| 2016 | 0.71 |
| 2015 | 0.53 |
| 2014 | 0.29 |
| 2013 | 0.1 |
| 2012 | 0.1 |
| 2011 | 0.11 |
| 2010 | 0.08 |
| 2009 | 0.08 |
| 2008 | 0.04 |
| 2007 | 0.08 |
| 2006 | 0.03 |
| 2005 | 0.02 |
| 2004 | 0.01 |
3SBio Revenue, EBIT, Net Income KYG8875G1029 · A14T7Q
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into 3SBio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by 3SBio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects 3SBio’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of 3SBio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into 3SBio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing 3SBio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on 3SBio’s growth potential.
3SBio Revenue, EBIT and net profit per share
| Date | 3SBio Revenue | 3SBio EBIT | 3SBio Net Income |
|---|---|---|---|
| 2029e | 13.32 B undefined | 0 undefined | 0 undefined |
| 2028e | 12.38 B undefined | 0 undefined | 0 undefined |
| 2027e | 10.82 B undefined | 2.59 B undefined | 1.38 B undefined |
| 2026e | 10.37 B undefined | 3.02 B undefined | 2.24 B undefined |
| 2025e | 9.59 B undefined | 2.77 B undefined | 2.12 B undefined |
| 2024e | 8.82 B undefined | 2.58 B undefined | 1.94 B undefined |
| 2023 | 7.82 B undefined | 2.45 B undefined | 1.55 B undefined |
| 2022 | 6.87 B undefined | 2 B undefined | 1.92 B undefined |
| 2021 | 6.38 B undefined | 1.76 B undefined | 1.65 B undefined |
| 2020 | 5.59 B undefined | 1.43 B undefined | 835.79 M undefined |
| 2019 | 5.32 B undefined | 1.22 B undefined | 973.72 M undefined |
| 2018 | 4.58 B undefined | 1.3 B undefined | 1.28 B undefined |
| 2017 | 3.73 B undefined | 1.17 B undefined | 935.39 M undefined |
| 2016 | 2.8 B undefined | 918.81 M undefined | 712.56 M undefined |
| 2015 | 1.67 B undefined | 464.35 M undefined | 526.28 M undefined |
| 2014 | 1.13 B undefined | 356.11 M undefined | 291.73 M undefined |
| 2013 | 875.4 M undefined | 193.8 M undefined | 95.9 M undefined |
| 2012 | 669.9 M undefined | 128.8 M undefined | 102.4 M undefined |
| 2011 | 541.6 M undefined | 121.6 M undefined | 108.6 M undefined |
| 2010 | 418.6 M undefined | 88.1 M undefined | 81.3 M undefined |
| 2009 | 316.9 M undefined | 85 M undefined | 83.4 M undefined |
| 2008 | 243.2 M undefined | 48.2 M undefined | 39.5 M undefined |
| 2007 | 180.2 M undefined | 49.6 M undefined | 81.5 M undefined |
| 2006 | 127.8 M undefined | 39.7 M undefined | 30.5 M undefined |
| 2005 | 102 M undefined | 23.9 M undefined | 16.1 M undefined |
| 2004 | 77.2 M undefined | 12.6 M undefined | 6.6 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 77.2 M CNY | 12.6 M CNY | 6.6 M CNY |
| 2005 | 102 M CNY | 23.9 M CNY | 16.1 M CNY |
| 2006 | 127.8 M CNY | 39.7 M CNY | 30.5 M CNY |
| 2007 | 180.2 M CNY | 49.6 M CNY | 81.5 M CNY |
| 2008 | 243.2 M CNY | 48.2 M CNY | 39.5 M CNY |
| 2009 | 316.9 M CNY | 85 M CNY | 83.4 M CNY |
| 2010 | 418.6 M CNY | 88.1 M CNY | 81.3 M CNY |
| 2011 | 541.6 M CNY | 121.6 M CNY | 108.6 M CNY |
| 2012 | 669.9 M CNY | 128.8 M CNY | 102.4 M CNY |
| 2013 | 875.4 M CNY | 193.8 M CNY | 95.9 M CNY |
| 2014 | 1.13 B CNY | 356.11 M CNY | 291.73 M CNY |
| 2015 | 1.67 B CNY | 464.35 M CNY | 526.28 M CNY |
| 2016 | 2.8 B CNY | 918.81 M CNY | 712.56 M CNY |
| 2017 | 3.73 B CNY | 1.17 B CNY | 935.39 M CNY |
| 2018 | 4.58 B CNY | 1.3 B CNY | 1.28 B CNY |
| 2019 | 5.32 B CNY | 1.22 B CNY | 973.72 M CNY |
| 2020 | 5.59 B CNY | 1.43 B CNY | 835.79 M CNY |
| 2021 | 6.38 B CNY | 1.76 B CNY | 1.65 B CNY |
| 2022 | 6.87 B CNY | 2 B CNY | 1.92 B CNY |
| 2023 | 7.82 B CNY | 2.45 B CNY | 1.55 B CNY |
| 2024e | 8.82 B CNY | 2.58 B CNY | 1.94 B CNY |
| 2025e | 9.59 B CNY | 2.77 B CNY | 2.12 B CNY |
| 2026e | 10.37 B CNY | 3.02 B CNY | 2.24 B CNY |
| 2027e | 10.82 B CNY | 2.59 B CNY | 1.38 B CNY |
| 2028e | 12.38 B CNY | 0 CNY | 0 CNY |
| 2029e | 13.32 B CNY | 0 CNY | 0 CNY |
3SBio stock margins KYG8875G1029 · A14T7Q
The 3SBio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of 3SBio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for 3SBio.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the 3SBio's sales revenue. A higher gross margin percentage indicates that the 3SBio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the 3SBio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the 3SBio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the 3SBio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the 3SBio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the 3SBio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
3SBio Margin History
| 3SBio Gross margin | 3SBio Profit margin | 3SBio EBIT margin | 3SBio Profit margin |
|---|---|---|---|
| 2029e | 84.98 % | 0 % | 0 % |
| 2028e | 84.98 % | 0 % | 0 % |
| 2027e | 84.98 % | 23.94 % | 12.75 % |
| 2026e | 84.98 % | 29.08 % | 21.58 % |
| 2025e | 84.98 % | 28.9 % | 22.08 % |
| 2024e | 84.98 % | 29.26 % | 22.04 % |
| 2023 | 84.98 % | 31.37 % | 19.82 % |
| 2022 | 82.61 % | 29.13 % | 27.9 % |
| 2021 | 82.67 % | 27.61 % | 25.87 % |
| 2020 | 80.98 % | 25.55 % | 14.96 % |
| 2019 | 82.6 % | 22.85 % | 18.31 % |
| 2018 | 80.86 % | 28.44 % | 27.86 % |
| 2017 | 81.89 % | 31.34 % | 25.05 % |
| 2016 | 85.62 % | 32.85 % | 25.47 % |
| 2015 | 85.54 % | 27.75 % | 31.45 % |
| 2014 | 92.26 % | 31.49 % | 25.8 % |
| 2013 | 90.5 % | 22.14 % | 10.95 % |
| 2012 | 89.48 % | 19.23 % | 15.29 % |
| 2011 | 89.27 % | 22.45 % | 20.05 % |
| 2010 | 90.04 % | 21.05 % | 19.42 % |
| 2009 | 92.05 % | 26.82 % | 26.32 % |
| 2008 | 91.08 % | 19.82 % | 16.24 % |
| 2007 | 90.34 % | 27.52 % | 45.23 % |
| 2006 | 90.92 % | 31.06 % | 23.87 % |
| 2005 | 84.8 % | 23.43 % | 15.78 % |
| 2004 | 80.57 % | 16.32 % | 8.55 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 80.57 % | 16.32 % | 8.55 % |
| 2005 | 84.8 % | 23.43 % | 15.78 % |
| 2006 | 90.92 % | 31.06 % | 23.87 % |
| 2007 | 90.34 % | 27.52 % | 45.23 % |
| 2008 | 91.08 % | 19.82 % | 16.24 % |
| 2009 | 92.05 % | 26.82 % | 26.32 % |
| 2010 | 90.04 % | 21.05 % | 19.42 % |
| 2011 | 89.27 % | 22.45 % | 20.05 % |
| 2012 | 89.48 % | 19.23 % | 15.29 % |
| 2013 | 90.5 % | 22.14 % | 10.95 % |
| 2014 | 92.26 % | 31.49 % | 25.8 % |
| 2015 | 85.54 % | 27.75 % | 31.45 % |
| 2016 | 85.62 % | 32.85 % | 25.47 % |
| 2017 | 81.89 % | 31.34 % | 25.05 % |
| 2018 | 80.86 % | 28.44 % | 27.86 % |
| 2019 | 82.6 % | 22.85 % | 18.31 % |
| 2020 | 80.98 % | 25.55 % | 14.96 % |
| 2021 | 82.67 % | 27.61 % | 25.87 % |
| 2022 | 82.61 % | 29.13 % | 27.9 % |
| 2023 | 84.98 % | 31.37 % | 19.82 % |
| 2024e | 84.98 % | 29.26 % | 22.04 % |
| 2025e | 84.98 % | 28.9 % | 22.08 % |
| 2026e | 84.98 % | 29.08 % | 21.58 % |
| 2027e | 84.98 % | 23.94 % | 12.75 % |
| 2028e | 84.98 % | 0 % | 0 % |
| 2029e | 84.98 % | 0 % | 0 % |
3SBio Aktienanalyse
What does 3SBio do?
3SBio Inc. is a biopharmaceutical company from China that specializes in the research, development, manufacturing, and marketing of biological products. It was founded in 1993 in Shenyang, a city in northeast China, and its headquarters are now in Beijing. 3SBio's business model is based on the development and manufacturing of biopharmaceuticals that are used to treat cancer, autoimmune diseases, and other serious illnesses. The company focuses on biological medicines such as proteins, antibodies, and peptides that are produced using genetic technology. 3SBio operates a wide range of business sectors, including the manufacturing and sale of biopharmaceutical products, the manufacturing and sale of generics and biosimilar products, and research and development in the biotechnology field. The company also has several subsidiaries and joint ventures, including 3SBio International Holding, Sunshine Guojian Pharmaceutical, and Target Pharma. A well-known product of 3SBio is erythropoietin (EPO), which is used in the treatment of anemia. The company also has a portfolio of other biopharmaceutical products that are used to treat cancer, autoimmune diseases, and other serious illnesses. The history of 3SBio goes back to 1993 when it was founded as Shenyang Sunshine Pharmaceutical. In 2001, the company was renamed "Shenyang Sunshine Pharmaceutical Co. Ltd. 3S Bio" and focused on biological therapy. In 2007, the company successfully listed on the Hong Kong Stock Exchange and received the name 3SBio. In 2013, the company was privatized and acquired by a consortium of Chinese investment companies. 3SBio has a strong presence in China and is also expanding into international markets. The company has distribution partnerships in Asia, Europe, and North America, and plans to enter more markets. Overall, 3SBio is a leading company in China in the field of biopharmaceuticals that focuses on the treatment of serious illnesses. The company aims to be a leader in research and development, as well as in the manufacturing and sale of innovative products, and to expand its presence in global markets. 3SBio ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding 3SBio's Profit Margins
The profit margins of 3SBio represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of 3SBio's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating 3SBio's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
3SBio's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When 3SBio’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about 3SBio Stock
How has the profit developed compared to last year?
The profit has increased by 25.41% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does 3SBio publish its earnings?
3SBio publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of 3SBio?
The profits of 3SBio are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of 3SBio?
You can learn more about the earnings of 3SBio by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does 3SBio pay?
Over the past 12 months, 3SBio paid a dividend of 0.1 CNY . This corresponds to a dividend yield of about 1.67 %. For the coming 12 months, 3SBio is expected to pay a dividend of 0.11 CNY.
What is the dividend yield of 3SBio?
The current dividend yield of 3SBio is 1.67 %.
When does 3SBio pay dividends?
3SBio pays a quarterly dividend. This is distributed in the months of July, July, July, August.
How secure is the dividend of 3SBio?
3SBio paid dividends every year for the past 0 years.
What is the dividend of 3SBio?
For the upcoming 12 months, dividends amounting to 0.11 CNY are expected. This corresponds to a dividend yield of 1.85 %.
In which sector is 3SBio located?
3SBio is assigned to the 'Health' sector.
Wann musste ich die Aktien von 3SBio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of 3SBio from 8/5/2024 amounting to 0.25 CNY, you needed to have the stock in your portfolio before the ex-date on 7/22/2024.
When did 3SBio pay the last dividend?
The last dividend was paid out on 8/5/2024.
What was the dividend of 3SBio in the year 2023?
In the year 2023, 3SBio distributed 0.2 CNY as dividends.
In which currency does 3SBio pay out the dividend?
The dividends of 3SBio are distributed in CNY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von 3SBio
Our stock analysis for 3SBio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 3SBio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
